Clinical Trials in Netherlands

• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended
  2023-508085-15-00 Phase III Chronic Obstructive Pulmonary Disease Sanofi-Aventis Recherche & Developpement
• Men4age study Ended
  2024-513640-29-00 Phase IV Invasive meningococcal disease, sepsis, meningitis Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended
  2022-501234-37-00 Phase I (FiH) Solid Tumours Regeneron Pharmaceuticals Inc.
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended
  2023-506669-70-00 Phase III Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Alexion Pharmaceuticals Inc.
• Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended
  2023-503231-17-00 Phase III Unresectable Pleural Mesothelioma AstraZeneca AB
• A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3 Ended
  2022-501766-22-01 Phase I (Other) Glioma expressing DLL3 Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
• Selective Treatment of Oral Povorcitinib in Vitiligo Study 1 (STOP-V1) Ended
  2023-505782-86-00 Phase III Vitiligo Incyte Corp.
• KetCRPS-2 Ended
  2024-511877-31-00 Phase IV Complex regional pain syndrome Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Ended
  2023-504865-21-00 Phase III Essential Thrombocythemia patients who have an inadequate re… Merck Sharp & Dohme LLC
• A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radi… Ended
  2023-506301-20-00 Phase I/II Tuberous Sclerosis Complex (TSC) Grin Therapeutics Inc.
• A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended
  2023-506195-27-00 Phase III non-segmental vitiligo AbbVie Deutschland GmbH & Co. KG
• A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab i… Ended
  2023-506948-17-00 Phase III Previously Untreated Chronic Lymphocytic Leukemia BeOne Medicines AG
• A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati… Ended
  2023-504124-26-00 Phase III Chronic Kidney Disease and High Proteinuria AstraZeneca AB
• IAVI C110 HIV Vaccine Trial Ended
  2023-508157-15-01 Phase I Human Immunodeficiency Virus (HIV) International AIDS Vaccine Initiative Inc.
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended
  2022-502161-19-00 Phase III Chronic Spontaneous Urticaria Novartis Pharma AG
• A Study of Mirikizumab (LY3074828) in Pediatric Participants with Crohn’s Disease (AMAY) Ended
  2024-511472-32-00 Phase III Crohn's Disease Eli Lilly & Co.
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended
  2023-504816-14-00 Phase III Endometrial cancer Merck Sharp & Dohme LLC
• A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intrav… Ended
  2023-506737-30-00 Phase I (FiH) Duchenne Muscular Dystrophy Biomarin Pharmaceutical Inc.
• A clinical Study to Evaluate Metreleptin Treatment in Subjects with Partial Lipodystrophy over 12-Month Timeframe Ended
  2022-501799-24-00 Phase III partial lipodystrophy Chiesi Farmaceutici S.p.A.
• Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease Ended
  2023-504471-25-00 Phase III Fibrotic Lung Disease United Therapeutics Corp.
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended
  2022-502446-27-00 Phase III Relapsed or Refractory Myeloma Janssen - Cilag International
• A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers. Ended
  2023-507059-32-00 Phase I (Other) To restore coagulation in patients taking DOACs who are expe… VarmX B.V.
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended
  2023-503827-25-01 Phase III Non-Small Cell Lung Cancer (NSCLC) Seagen Inc.
• A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Ended
  2023-507460-39-00 Phase II/III Adult patients with resectable muscle-invasive urothelial ca… Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Showing 1,489–1,512 of 2,591 trials